All In MedTech

Device Trial Radar · NCT07026877

Endovascular Repair With Fenestrated TREO Stent-Graft System in AAA

A Prospective, Multicenter, Non-Blinded, Non-Randomized Pivotal Study of the Fenestrated TREO Stent-Graft System in Subjects With Abdominal Aortic Aneurysms Requiring a Fenestrated Graft and Suitable for Endovascular Repair

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

20

Planned (sponsor's estimate)

Start

Nov 18, 2025

Primary completion

May 29, 2027

Study completion May 29, 2030

Sponsor

Lead sponsor
Bolton MedicalNot on our public-company list
Sponsor type
Industry
First posted
Jun 18, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the Fenestrated TREO Stent-Graft System works to treat abdominal aneurysms in adults. An abdominal aneurysm is a bulge in the main blood vessel (the aorta) which carries blood from the heart, through the chest and abdomen. It will also learn about the safety of Fenestrated TREO Stent-Graft System. The main question it aims to answer is: Can the the Fenestrated TREO Stent-Graft System be used to treat participants with a specific type of abdominal aneurysm called a juxtarenal abdominal aortic aneurysm? Participants will: Have the the Fenestrated TREO Stent-Graft System implanted via an endovascular surgical procedure and visit the hospital for a follow up period of 5 years, for checkups, tests and imaging scans.

Conditions

  • Abdominal Aortic Aneurysms (AAA)

Interventions

  • Fenestrated TREO Stent Graft SystemDevice

    The Fenestrated TREO Stent-Graft System is a modular, endoluminal, over-the-wire system intended for the endovascular treatment of juxtarenal and pararenal to paravisceral aneurysms requiring a fenestrated stent-graft and having suitable morphology. The system is composed of the following components: Fenestrated TREO Bifurcate Stent-Graft - The main body fenestrated bifurcate provides the following; proximal seal, fenestrations and gates for connection to the leg extensions. Bridging Stents - The bridging stent connects the main body bifurcated device to the target visceral artery allowing the target anatomy to maintain perfusion while keeping the pathology sealed TREO Leg and Straight Extension Stent-Grafts: The Leg Extension and Straight Extension stent-grafts are used to complete coverage of the pathology from the main body bifurcated device to the distal landing zones (usually the common iliac artery just proximal to the iliac bifurcation).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with absence of a major adverse event (Primary Safety Endpoint)Time frame: 30-day post-procedure
  2. Proportion of patients with successful aneurysm treatment through 12-months post-implant procedure (Primary Effectiveness Endpoint)Time frame: 12 months post-procedure
  3. Successful delivery and deployment of the aortic stent-graft and all modular stent-graft components (Technical Success)Time frame: Evaluated 30-days post procedure

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • UC Health Memorial

    Colorado Springs, Colorado

  • Tampa General Hospital

    Tampa, Florida

  • Brigham and Women's Hospital

    Boston, Massachusetts

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.